CD8+ T-cell immunity to HIV infection

Clinics in Laboratory Medicine

Volumn 22, Issue 3, 2002, Pages 773-797

  Piazza, Paolo ^a   Fan, Zheng ^a   Rinaldo Jr , Charles R ^a,b  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD8 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; KIDNEY DYSFUNCTION; LIPODYSTROPHY; PRIORITY JOURNAL; REVIEW; SERODIAGNOSIS; T LYMPHOCYTE; THROMBOCYTOPENIA; VIRUS LOAD;

CD8-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV-1; HUMANS; T-LYMPHOCYTE SUBSETS;

EID: 0036715389     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-2712(02)00006-9     Document Type: Review

References (162)

1. Extensive variation of human immunodeficiency virus type-1 in vivo
2. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV-1 Cohort Study
3. The cytotoxic T-lymphocyte response in HIV-1 infection
4. Accessing complexity: The dynamics of virus-specific T cell responses
5. Immunobiology of dendritic cells
6. HLA-peptide tetrameric complexes
7. Counting antigen-specific CD8 T cells: A reevaluation of bystander activation during viral infection
8. Functionally inert HIV-1-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children
9. Phenotypic analysis of antigen-specific T lymphocytes
10. Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: Relationship to viral load in untreated HIV infection
11. Monitoring HIV-specific CD8+ T cell responses by intracellular cytokine production
12. Accessing Epstein-Barr virus-specific T-cell memory with peptide-loaded dendritic cells
13. Identification of an HLA-A*0201 restricted CD8+ T cell epitope for the glycoprotein B homolog of human herpesvirus 8
14. Identification of subdominant cytotoxic T lymphocyte epitopes encoded by autologous HIV type 1 sequences, using dendritic cell stimulation and computer-driven algorithm
15. Immune responses in HIV-exposed seronegatives: Have they repelled the virus?
16. HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi
17. New insights into HIV-1 specific cytotoxic T-lymphocyte responses in exposed, persistently seronegative Kenyan sex workers
18. Cytotoxic T cell responses to multiple conserved HIV-1 epitopes in HIV-1-resistant prostitutes in Nairobi
19. HIV-1-specific cytotoxic T cells in HIV-1-exposed but uninfected Gambian women
20. Immune defence against HIV-1 infection in HIV-1 exposed seronegative persons
21. HIV-1 receptors and cell tropism
22. Lack of infection in HIV-exposed individuals is associated with a strong CD8(+) cell noncytotoxic anti-HIV response
23. Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection
24. How important is the 'quality' of the cytotoxic T lymphocyte (CTL) response in protection against HIV-1 infection?
25. Selective induction of protective MHC class I-restricted CTL in the intestinal lamina propria of rhesus monkeys by transient SIV infection of the colonic mucosa
26. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
27. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
28. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
29. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques
30. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques
31. Effects of in vivo CD8(+) T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine
32. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes
33. Immunologic and virologic analyses of an acutely HIV type 1-infected patient with extremely rapid disease progression
34. Anti-HIV type 1 cytotoxic T lymphocyte effector activity and disease progression in the first 8 years of HIV type 1 infection of homosexual men
35. The importance of the innate immune system in controlling HIV infection and disease
36. Maintenance of large numbers of virus-specific CD8+ T cells in HIV-infected progressors and long-term nonprogressors
37. A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon
38. High viral burden in the presence of major HIV-1-specific CD8(+) T cell expansions: Evidence for impaired CTL effector function
39. Functional impairment of simian immunodeficiency virus-specific CD8+ T cells during the chronic phase of infection
40. Viral immune evasion due to persistence of activated T cells without effector function
41. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
42. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection
43. The emerging role of CD40 ligand in HIV infection
44. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function
45. Human immunodeficiency virus-specific circulating CD8 T lymphocytes have down-modulated CD3zeta and CD28, key signaling molecules for T-cell activation
46. Circulating CD8 T lymphocytes in human immunodeficiency virus-infected individuals have impaired function and downmodulate CD3 zeta, the signaling chain of the T-cell receptor complex
47. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection
48. HLA and HIV-1: Heterozygote advantage and B*35-Cw*04 disadvantage
49. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS
50. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors
51. Major expansion of CD8+ T cells with predominant V beta usage during primary immune response to HIV
52. Oligoclonal expansions of CD8+ T cells in chronic HIV infection are antigen specific
53. Viral subversion of the immune system
54. Co-evolution of human immunodeficiency virus and cytotoxic T-lymphocyte responses
55. Understanding cytotoxic T-lymphocyte escape during simian immunodeficiency virus infection
56. Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection
57. Dominance of CD8 responses specific for epitopes bound by a single major histocompatibility complex class I molecule during the acute phase of viral infection
58. Anti-viral pressure exerted by HIV-1-1-specific cytotoxic T lymphocytes (CTL) during primary infection demonstrated by rapid selection of CTL escape virus
59. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia
60. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers
61. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS
62. Evolution and transmission of stable CTL escape mutations in HIV-1 infection
63. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses
64. A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation
65. The flexibility of the TCR allows recognition of a large set of naturally occurring epitope variants by HIV-1-specific cytotoxic T lymphocytes
66. Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes
67. Copresentation of natural HIV-1 agonist and antagonist ligands fails to induce the T cell receptor signaling cascade
68. T-cell receptor-mediated anergy of a human immunodeficiency virus (HIV-1) gp120-specific CD4(+) cytotoxic T-cell clone, induced by a natural HIV-1 type 1 variant peptide
69. Repression of MHC class I gene promoter activity by two-exon Tat of HIV
70. The human immunodeficiency virus type 1 (HIV-1) Vpu protein interferes with an early step in the biosynthesis of major histocompatibility complex (MHC) class I molecules
71. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein
72. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes
73. HIV-1 Nef blocks transport of MHC class I molecules to the cell surface via a PI 3-kinase-dependent pathway
74. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-1-infected cells from NK cells
75. Evasion of cytotoxic T lymphocyte (CTL) responses by nef-dependent induction of Fas ligand (CD95L) expression on simian immunodeficiency virus-infected cells
76. Induction of Fas ligand expression by HIV involves the interaction of Nef with the T cell receptor zeta chain
77. Chemokine-receptor activation by env determines the mechanism of death in HIV-infected and uninfected T lymphocytes
78. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes
79. Costimulation of naive CD8(+) lymphocytes induces CD4 expression and allows human immunodeficiency virus type 1 infection
80. Isolation of primary HIV-1 that target CD8+ T lymphocytes using CD8 as a receptor
81. Evidence of productively infected CD8+ T cells in patients with AIDS: Implications for HIV-1 pathogenesis
82. Long-term nonprogression in HIV infection: Methodological issues and scientific priorities. Report of an international European community-National Institutes of Health Workshop
83. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection
84. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics
85. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors
86. An activated CD8+ T cell phenotype correlates with anti-HIV activity and asymptomatic clinical status
87. Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: Implications for the development of therapeutic strategies
88. Type 1 cytokine production and low prevalence of viral isolation correlate with long-term nonprogression in HIV infection
89. Frequency and function of HIV-specific CD8(+) T cells
90. Even individuals considered as long-term nonprogressors show biological signs of progression after 10 years of human immunodeficiency virus infection
91. Characterization of three nef-defective human immunodeficiency virus type 1 strains associated with long-term nonprogression
92. HIV chemotherapy
93. Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy
94. Initiation of antiretroviral therapy during primary HIV-1 infection induces rapid stabilization of the T-cell receptor beta chain repertoire and reduces the level of T-cell oligoclonality
95. Reconstitution of CD4+ T lymphocytes in HIV-infected individuals following antiretroviral therapy
96. Changes in thymic function with age and during the treatment of HIV infection
97. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy
98. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy
99. Anti-human immunodeficiency virus type 1 (HIV-1) CD8(+) T-lymphocyte reactivity during combination antiretroviral therapy in HIV-1-infected patients with advanced immunodeficiency
100. Changes in frequency of HIV-1-specific cytotoxic T cell precursors and circulating effectors after combination antiretroviral therapy in children
101. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
102. Long-term protease inhibitor-containing therapy results in limited improvement in T cell function but not restoration of interleukin-12 production in pediatric patients with aids
103. Immunologic and virologic responses to HAART in severely immunocompromised HIV-1-infected children
104. Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy
105. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens
106. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects
107. Structured treatment interruptions for the management of HIV infection
108. Immune control of HIV-1-1 after early treatment of acute infection
109. Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection
110. Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy
111. Control of HIV-1 despite the discontinuation of antiretroviral therapy
112. Dynamics of HIV-1-specific CD8+ T lymphocytes with changes in viral load
113. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy
114. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption
115. HIV-1 dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection
116. Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment
117. Control of SIV rebound through structured treatment interruptions during early infection
118. Immunopathogenesis of human immunodeficiency virus: Implications for immune-based therapies
119. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys
120. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
121. Cultured blood dendritic cells retain HIV-1 antigen-presenting capacity for memory CTL during progressive HIV-1 infection
122. Delivery of liposome-encapsulated HIV type 1 proteins to human dendritic cells for stimulation of HIV type 1-specific memory cytotoxic T lymphocyte responses
123. Restoration of anti-human immunodeficiency virus type 1 (HIV-1) responses in CD8+ T cells from late-stage patients on prolonged antiretroviral therapy by stimulation in vitro with HIV-1 protein-loaded dendritic cells
124. Efficient priming of protein antigen-specific human CD4(+) T cells by monocyte-derived dendritic cells
125. Induction of anti-human immunodeficiency virus type 1 (HIV-1) CD8+- and CD4+-T-cell reactivity by dendritic cells loaded with HIV-1 X4-infected apoptotic cells
126. The susceptibility to X4 and R5 human immunodeficiency virus-1 strains of dendritic cells derived in vitro from CD34+ hematopoietic progenitor cells is primarily determined by their maturation stage
127. Immature dendritic cells selectively replicate macrophage tropic (M-tropic) human immunodeficiency virus type 1, while mature cells efficiently transmit both M- and T-tropic virus to T cells
128. Improbability of effective vaccination against human immunodeficiency virus because of its intracellular transmission and rectal portal of entry
129. Current progress in the development of human immunodeficiency virus vaccines: Research and clinical trials
130. Challenges and opportunities for development of an AIDS vaccine
131. Cellular HIV-1 immune responses in natural infection and after genetic immunization
132. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers
133. Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells
134. Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys
135. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge
136. HIV-1 vaccine-induced immune responses which correlate with protection from SHIV infection: Compiled preclinical efficacy data from trials with ten different HIV-1 vaccine candidates
137. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P)
138. A recombinant avipoxvirus HIV-1 vaccine expressing interferon-gamma is safe and immunogenic in macaques
139. Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): Dependence on route of challenge exposure
140. DNA priming and recombinant pox virus boosters for an AIDS vaccine
141. Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen
142. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
143. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
144. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes
145. One step forwards, one step back
146. AIDS virus-specific cytotoxic T lymphocytes in lung disorders
147. HIV-specific cytotoxic T lymphocytes in seropositive individuals
148. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen
149. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination
150. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment
151. Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection
152. Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef
153. Evaluation of canarypox-induced CD8(+) responses following immunization by measuring the effector population IFN gamma production
154. Protection from pathogenic SIV challenge using multigenic DNA vaccines
155. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency virus (SHIV(89.6)P)
156. The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins
157. Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen
158. Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model
159. Recombinant modified vaccinia virus Ankarasimian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer
160. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with RGP120
161. Cytotoxic T cells and neutralizing antibodies induced in rhesus monkeys by virus-like particle HIV vaccines in the absence of protection from SHIV infection